Synthetic intelligence (AI) and revolutionary pharmaceutical remedies within the weight-loss market have introduced newfound curiosity to the expertise and healthcare sectors.
One firm working throughout each AI and weight reduction is Novo Nordisk (NYSE: NVO). The Danish pharmaceutical large is the brains behind in style diabetes and weight problems care medicines Ozempic, Rybelsus, and Wegovy.
Let’s dig into how the corporate is making waves in each AI expertise and drug growth.
The intersection of healthcare and expertise
From statistical evaluation of knowledge in scientific trials to machines altering and honing the molecular buildup of potential breakthrough medicines, expertise and healthcare are shut allies.
Novo Nordisk was lengthy recognized for its insulin remedies. However a dedication to affected person care and product innovation helped the corporate develop new medicines and broaden its horizons, specifically within the weight-loss area.
The corporate’s growth of a compound referred to as semaglutide gave rise to Ozempic, Rybelsus, and Wegovy. Ozempic and Rybelsus are used to deal with sufferers with diabetes. In contrast, Wegovy is authorised by the Meals and Drug Administration (FDA) for power weight administration. All three of those blockbuster medication belong to a category of remedies referred to as glucagon-like peptide-1 (GLP-1) agonists.
Whereas these medical discoveries have been met with reward, Novo Nordisk is not resting on its laurels. The corporate stays dedicated to innovation, and administration is dropping breadcrumbs on how synthetic intelligence (AI) will play a job.
Investing for the long run
On the floor, use instances surrounding AI within the pharmaceutical trade could appear apparent. Novo Nordisk has outlined that synthetic intelligence (AI) helps the corporate course of bigger volumes of knowledge from broader cohorts of sufferers.
In essence, this could theoretically enhance the variety of drug candidates dropped at scientific trials. However extra importantly, AI can play a job in figuring out when these goal medicines are able to be examined, thereby mitigating the danger of dashing into a brand new product trial earlier than it is prepared.
Story continues
Just a few days in the past, information broke that the Novo Nordisk Basis awarded a contract to France-based information firm Eviden to assist develop AI in Denmark. Per the deal, Eviden will configure and set up a supercomputer constructed on Nvidia’s {hardware} and software program system. The supercomputer, referred to as Gefion, will boast over 1,500 Nvidia graphics processing items (GPUs) and leverage the chipmaker’s CUDA software program service.
The genesis of constructing the supercomputer is to assist spearhead developments in analysis and innovation throughout healthcare, life sciences, and sustainable vitality.
Whereas a challenge like this may occasionally appear extra aspirational than something, Novo Nordisk is not the primary healthcare firm to get entangled with quantum computing. IBM put in its personal quantum laptop, Quantum System One, on the Cleveland Clinic to bolster analysis and growth.
What may this imply for Novo Nordisk?
Accelerated computing might help course of scientific information sooner and probably extra precisely. Consequently, drug corporations could possibly establish expanded indications or transfer by their pipeline of latest candidates extra rapidly.
Diabetes and weight problems care are already large markets which might be anticipated to develop for years. Analysis means that by 2050, there might be 1 billion diabetics worldwide. Furthermore, Novo Nordisk’s already-strong pipeline has me optimistic concerning the firm’s potential for the subsequent a number of years.
I’m inspired by Novo Nordisk’s foray in AI and optimistic that the expertise will assist strengthen the corporate’s long-term potential. Plus, Novo Nordisk’s involvement with the supercomputer shines a lightweight on one thing deeper. The corporate is finally serving to fund scientific analysis on a broader degree, and this might result in medical breakthroughs in many various areas.
To me, this showcases that Novo Nordisk locations a premium on affected person care — no matter if future breakthroughs impression the corporate’s core markets. I feel Novo Nordisk needs to be seen as a frontrunner within the healthcare area, and its give attention to AI-powered innovation mustn’t go missed.
Do you have to make investments $1,000 in Novo Nordisk proper now?
Before you purchase inventory in Novo Nordisk, take into account this:
The Motley Idiot Inventory Advisor analyst staff simply recognized what they consider are the 10 finest shares for buyers to purchase now… and Novo Nordisk wasn’t one among them. The ten shares that made the reduce may produce monster returns within the coming years.
Inventory Advisor supplies buyers with an easy-to-follow blueprint for achievement, together with steering on constructing a portfolio, common updates from analysts, and two new inventory picks every month. The Inventory Advisor service has greater than tripled the return of S&P 500 since 2002*.
See the ten shares
*Inventory Advisor returns as of March 21, 2024
Adam Spatacco has positions in Novo Nordisk and Nvidia. The Motley Idiot has positions in and recommends Nvidia. The Motley Idiot recommends Worldwide Enterprise Machines and Novo Nordisk. The Motley Idiot has a disclosure coverage.
Uncovering Hidden Gems: 1 AI-Powered Healthcare Inventory Set to Dominate the Market was initially revealed by The Motley Idiot
